Trial Search Results

A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

This is open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors that will be conducted in 3 parts (dose escalation, expansion to solid tumors, and expansion to T cell lymphomas). Part 3 Expansion will be conducted at Stanford to further evaluate the safety and efficacy in patients with T-cell lymphomas.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Trillium Therapeutics Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: TTI-621
  • Drug: TTI-621 plus Rituximab
  • Drug: TTI-621 plus Nivolumab

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   1. Advanced measurable malignancy

   2. Adequate hematologic status

   3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1
   prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will
   be considered a systemic therapy. Local radiation and topical agents are not systemic
   therapies.

   4. Adequate coagulation function

   5. Adequate hepatic function

   6. Adequate renal function

Exclusion Criteria:

   1. Known, current central nervous system disease involvement or untreated brain
   metastases

   2. Allogeneic transplant within 30 days prior to the planned start of treatment or
   subjects with active graft-vs-host disease with the exception of Grade 1 skin
   involvement

   3. History of hemolytic anemia or bleeding diathesis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All